Entries by Thomas Gabrielczyk

GMO acreage growing

GMO world market adoption is further growing. GMO cultivation area in 2016 increased to 185.1 million hectares versus 2015 (179.7m hectares), 3% up globally, and from 116,870 in 2015 to 136,363 hectares, 17% up, in the EU. 

Another great year for Swiss biotech

With an impressive 11.7% growth in sales compared with 2015, the Swiss biotech sector has grown more strongly in 2016 than the years before. However, after three years of growth, Swiss biotech companies collected almost CHF100m less than in the previous year, according to the most recent Swiss Biotech Report.

German biotech on the rise

The Biotechnology in Germany is a growth engine. According to a new report, all key figures such as employees, turnover and R&D expenditure were at an all-time high in 2016.

€37.5 million for Vivet Therapeutics

The french biotechnology company Vivet Therapeutics has raised €37.5 million in a Series A financing round. Amongst others, Novartis Venture Fund and Roche Venture Fund were involved.

Abivax’ shares jump on new Phase IIa HIV data

The French biotech said that its lead therapeutic candidate demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients. Following the news, the company’s share price more than doubled.

Verona Pharma raised US-$77.8m at NASDAQ

British respiratory disease specialist Verona Pharma plc (VRNA) has raised US-$77.8m (€73,96m) at NASDAQ through the issuance of 5,768,000 American Depositary Shares (ADS) – each ADS representing eight ordinary shares – at a price of US-$13.50 per ADS.

Epigenomics in €171m take-over

Epigenomics and minority shareholder Cathay Fortune International Company have agreed for Cathay to take over the Berlin-based diagnostics company for €7.52 per share – a premium of almost 50%.